# Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

> **NCT03564340** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 890 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Primary Peritoneal Cancer
- Recurrent Endometrial Cancer
- Endometrial Cancer
- Low-grade Serous Ovarian Cancer

## Interventions

- **DRUG:** Ubamatamab
- **DRUG:** Cemiplimab
- **DRUG:** Sarilumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03564340
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-21
- **Primary completion:** 2027-05-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 890 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564340, "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT03564340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*